ClinicalTrials.gg
Not yet recruitingNCT07939386Updated Nov 16, 2026

Comparison of the Effect of Lung-protective Ventilation on Optic Nerve Sheath Diameter in Obese and Non-obese Patients

An interventional study of Alveolar recruitment maneuver and individualized PEEP and Optic nerve sheath diameter (ONSD) in Obese Patients, Laparoscopic Abdominal Surgery and Optic Nerve Sheath Diameter Measurement, sponsored by Eskisehir Osmangazi University. Not yet recruiting. Open to participants aged 25 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Eskisehir Osmangazi University · Not applicable, Interventional, and Diagnostic

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Non-randomized
Ages
25 Years and older
Sex
All
01

Study summary

The gol of this prospective observational study is to evaluate the effect of recruitment maneuvers-employed as part of an intraoperative lung-protective ventilation strategy-and individualized positive end-expiratory pressure (PEEP) on intracranial pressure, as assessed by measuring the optic nerve sheath diameter, in both obese and non-obese patients undergoing laparoscopic surgery.

Read the detailed description

Laparoscopy is widely used due to its advantages, such as less blood loss, reduced postoperative pain, and faster recovery. However, pneumoperitoneum increases thoracoabdominal pressure, which decreases venous drainage from the brain and increases cerebral blood flow and intracranial pressure (ICP). The optic nerve sheath diameter (ONSD) measurement via ultrasound is a non-invasive and reliable method for assessing ICP.

The prevalence of obesity has increased substantially over recent decades, accompanied by a growing number of obese patients undergoing laparoscopic surgery. Obesity is associated with increased intra-abdominal pressure, which may contribute to an increase in ONSD. Furthermore, the additional rise in intra-abdominal pressure induced by pneumoperitoneum may exacerbate these effects, potentially placing obese patients at greater risk of alterations in cerebral haemodynamics during laparoscopic procedures.

Atelectasis occurs in roughly 90% of all patients undergoing general anaesthesia and can persist for weeks after operation. Intraoperative lung-protective ventilation has been recommended to reduce postoperative pulmonary complications after abdominal and/or laparoscopic surgery and also in obese patients. Decreasing compliance caused by surgical/ anaesthesia factors (i.e. pneumoperitoneum, positioning, and circuit disconnect) should be treated by appropriate interventions. Individualised PEEP and alveolar recruitment manoeuvres can prevent and reverse alveolar collapse, respectively.

However, the effects of these interventions on cerebral haemodynamics, particularly ICP as assessed indirectly by ONSD measurement, remain insufficiently understood in obese and non-obese patients undergoing laparoscopic surgery.

The gol of this prospective observational study is to evaluate the effect of recruitment maneuvers and individualized PEEP- as part of intraoperative lung-protective ventilation strategy- on intracranial pressure, as assessed by measuring the optic nerve sheath diameter (ONSD), in both obese and non-obese patients undergoing laparoscopic surgery.

02

Conditions studied

  • Obese Patients
  • Laparoscopic Abdominal Surgery
  • Optic Nerve Sheath Diameter Measurement
  • Intraoperative Lung Protective Ventilation

Browse trials for

Keywords

  • obesity
  • laparoscopic surgery
  • optic nerve sheath diameter
  • lung protective ventilation
03

In context

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's planned enrollment of 70 is close to the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eskisehir Osmangazi University is the lead sponsor of 154 studies on the registry; 28 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 25 years of age
  • American Soc,ety of Anesthesiology (ASA) status I-III
  • Scheduled to undergo laparoscopic abdominal surgery
  • With an expected pneumoperitoneum duration of ≥1 hour

Exclusion criteria

Exclusion Criteria:

  • Patients with ocular disease
  • Patients who have undergone cranial or ocular surgery
  • Patients with a history of laparotomy
  • Individuals with bullous lung disease
  • Patients with uncontrolled chronic obstructive lung disease
  • Patients with hemodynamic instability or decompensated heart failure
  • Patients who require conversion to an open surgical procedure for any reason
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Other
    Group O

    Obese patients with BMI ≥ 30 kg/m²

    Other: Alveolar recruitment maneuver and individualized PEEP · Procedure: Optic nerve sheath diameter (ONSD)

  • Other
    Group N

    Non-obese patients

    Other: Alveolar recruitment maneuver and individualized PEEP · Procedure: Optic nerve sheath diameter (ONSD)

Interventions

  • OtherAlveolar recruitment maneuver and individualized PEEP

    Following intubation and desufflation, an incremental alveolar recruitment maneuver (ARM) will be performed, in which the driving pressure is kept constant while the PEEP value is increased in a stepwise manner. The ARM will be performed in pressure control mode, maintaining pressure at a steady driving pressure with increments in PEEP until a peak pressure is achieved (35-40 cmH2) with a preestablished maximum PEEP. This will be maintained long enough to reopen the alveoli (5---10 breaths), and then pressure is reduced in a stepwise manner until the ideal PEEP is achieved (this being the PEEP level that produces the best Cdyn at the lowest driving pressure for a particular tidal volume setting)

  • ProcedureOptic nerve sheath diameter (ONSD)

    ONSD will be measured at a standard level of 3 mm behind using a lineer ultrasound transducer. The measurements will be performed by an anesthesiologist experienced in ONSD measurement. The eyes will be covered with drapes; subsequently, using an ultrasound-compatible gel, measurements of both of the patient's eyes will be taken in a transverse and a sagittal plane. The mean of these measurements will then be calculated to determine the ONSD value.

06

What researchers measure

Primary outcomes

  1. Optic nerve sheath diameter (ONSD)

    Perioperative ONSD will be measured 3 mm behind the eye globe with ultrasound

    Time frame: Perioperative/Periprocedural (t0-after anesthesia induction and entubation)

  2. Optic nerve sheath diameter (ONSD)

    Perioperative ONSD will be measured 3 mm behind the eye globe with ultrasound

    Time frame: Perioperative/Periprocedural (t1- following the recruitment maneuver and the adjustment of the individualized PEEP value)

  3. Optic nerve sheath diameter (ONSD)

    Perioperative ONSD will be measured 3 mm behind the eye globe with ultrasound

    Time frame: Perioperative/Periprocedural (t2- at the 30th minute of pneumoperitoneum)

  4. Optic nerve sheath diameter (ONSD)

    Perioperative ONSD will be measured 3 mm behind the eye globe with ultrasound

    Time frame: Perioperative/Periprocedural (t3 - after desufflation)

  5. Optic nerve sheath diameter (ONSD)

    Perioperative ONSD will be measured 3 mm behind the eye globe with ultrasound

    Time frame: Perioperative/Periprocedural (t4- following a subsequent recruitment maneuver)

  6. Optic nerve sheath diameter (ONSD)

    Perioperative ONSD will be measured 3 mm behind the eye globe with ultrasound

    Time frame: Perioperative/Periprocedural (t5- at the 30th minute in the recovery room)

Secondary outcomes

  1. MAP

    Noninvasive mean arterial pressure (mmHg)

    Time frame: Perioperative (Noninvasive mean arterial pressure will be recorded at the times when ONSD measurement is performed)

  2. HR

    Heart rate (beat/min)

    Time frame: Perioperative (Heart rate will be recorded at the times when ONSD measurement is performed)

  3. etCO2

    End-tidal carbon dioxide levels (mmHg)

    Time frame: Perioperative (End-tidal carbon dioxide levels will be recorded at the times when ONSD measurement is performed)

Other outcomes

  1. Airway pressures during mechanical ventilation

    Ppeak, Pplato, Driving pressure (∆P), PEEP levels (cmH20) will be recorded from the sama ventilation monitor screen

    Time frame: Perioperative (Ppeak, Pplato, Driving pressure (∆P), PEEP levels will be recorded at the times when ONSD measurement is performed)

  2. Postoperative complications

    Postoperative nause and vomiting (PONV)

    Time frame: PONV will be questioned at the 24th hours

  3. Postoperative complications

    Headache

    Time frame: Headache will be questioned at the 24th hours

  4. Postoperative complications

    Visual disturbance

    Time frame: Visual disturbance will be questioned at the 24th hours

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kim H, Seol T, Chang JE, Won D, Lee JM, Kim TK, Park EB, Hwang JY. The effect of obesity on optic nerve sheath diameter in patients undergoing laparoscopic gynecological surgery: a prospective observational study. J Anesth. 2025 Jun;39(3):408-415. doi: 10.1007/s00540-025-03482-1. Epub 2025 Mar 20. PubMed 40111534 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Nov 2027, 11 months later.

Of 3,690 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 3,853 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Nov 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939386
Responsible party
Gulay ERDOGAN KAYHAN (Professor Doctor, Eskisehir Osmangazi University) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Nov 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Gulay Erdogan Kayhan, Prof. Dr.
Contact
drgulayer@yahoo.com
905332560011
Muhammed Alpaslan Uludag, Research Assistant, MD
Contact
muho.78@live.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion